The FORA G71a Blood Glucose Monitoring System/TD-4274 Blood Glucose Monitoring System are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The alternative site testing in the FORA G71a Blood Glucose Monitoring System /TD-4274 Blood Glucose Monitoring System can be used only during steady-state blood glucose conditions.

Device Description

The system consists of three main products: the meter, test strips, and control solutions. These products have been designed, tested, and proven to work together as a system to produce accurate blood glucose test results. Use only FORA G71a / TD-4274 test strips and control solutions with the FORA G71a Blood Glucose Monitoring System / TD-4274 Blood Glucose Monitoring System.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and study for the FORA G71a / TD-4274 Blood Glucose Monitoring System:

1. Table of Acceptance Criteria and Reported Device Performance

The provided 510(k) summary does not explicitly state specific acceptance criteria or detailed performance metrics. Instead, it relies on demonstrating substantial equivalence to a predicate device. The key performance characteristic mentioned is "system accuracy."

Acceptance Criteria (Implied)	Reported Device Performance
Substantial Equivalence to Predicate Device (FORA G30/TD-4241) in performance characteristics, specifically "system accuracy."	"A comparison of system accuracy performance demonstrated that the FORA G71a blood glucose monitoring system / TD-4274 Blood Glucose Monitoring System and the currently marketed FORA G30/TD-4241 Blood Glucose Monitoring System are substantially equivalent."
Software verification and validation confirmed performance, safety, and effectiveness.	"Software verification and validation testing confirmed that the performance, safety and effectiveness of the FORA G71a blood glucose monitoring system / TD-4274 Blood Glucose Monitoring Systems are equivalent to the predicate device."

2. Sample Size Used for the Test Set and Data Provenance

The document does not specify the sample size used for the test set or the data provenance (e.g., country of origin, retrospective or prospective). It simply states that "A comparison of system accuracy performance demonstrated..." without providing details on the study design.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

The document does not mention the use of experts to establish ground truth. For blood glucose monitoring systems, ground truth is typically established by laboratory reference methods (e.g., YSI analyzer), rather than expert consensus on images or interpretations.

4. Adjudication Method for the Test Set

As experts are not mentioned in relation to ground truth, an adjudication method is not applicable in this context.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

A Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not performed or reported. This type of study is typically used for imaging interpretation devices where human readers' performance is being evaluated with and without AI assistance. A blood glucose monitor is a standalone diagnostic device.

6. Standalone Performance Study (Algorithm Only Without Human-in-the-Loop Performance)

Yes, a standalone performance study in the form of a "system accuracy performance" comparison was conducted. This type of device inherently operates in a "standalone" manner, providing a direct measurement without human interpretation beyond reading the displayed result. The comparison was to a predicate device, implying that the new device's readings were directly compared to those of the predicate device.

7. Type of Ground Truth Used

The document does not explicitly state the type of ground truth used, but for blood glucose monitoring systems, the ground truth is overwhelmingly laboratory reference methods (e.g., YSI glucose analyzer) on blood samples. The term "system accuracy performance" implies a comparison to such a reference method, or at least a comparison to the predicate device which would have been validated against a reference method.

8. Sample Size for the Training Set

The document does not mention a training set or its sample size. Glucose meters are typically developed and validated using a series of experiments and comparisons, not usually via a machine learning "training set" in the conventional sense of AI. The "modification in the software of the glucose meter" would have undergone internal development and testing, but not typically a labeled training data set as seen in AI/ML applications.

9. How the Ground Truth for the Training Set Was Established

As no training set is described, this information is not applicable and not provided.

Summary

{0}------------------------------------------------

Section 11. 510(k) Summary

510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.

The Assigned 510(k) number is: K093712

1. Submitter's Identification: TaiDoc Technology Corporation 6F, No.127, Wugong 2nd Rd., Wugu Township, Taipei County, 248, Taiwan
  Correspondence: Nicky Pan Regulatory Affairs Specialist Tel: +886-2-6625-8188 #1196 Fax: +886-2-6625-0288 Email: nicky@taidoc.com.tw

Date of submission: 11/30/2009

1. Device name:
  Proprietary name: FORA G71a blood glucose monitoring system TD-4274 blood glucose monitoring system

Regulatory information:

A. Regulation section: 21 CFR 862.1345 Glucose Test System
B. Classification: Class II
Product Code: C. CGA, Glucose Oxidase, Glucose
- NBW, System, Test, Blood Glucose, Over The Counter
D. Panel: Chemistry (75)

{1}------------------------------------------------

3. Intended Use:

This system is intended for use outside the body (in vitro diagnostic use only). It is used for the quantitative measurement of glucose in fresh capillary whole blood samples taken from the palm, forearm, upper arm, calf, thigh, or fingers. It is not intended for the diagnosis of or screening for diabetes mellitus, or for use on neonates.

This system provides you with plasma equivalent results.

1. Device Description:
  The system consists of three main products: the meter, test strips, and control solutions. These products have been designed, tested, and proven to work together as a system to produce accurate blood glucose test results. Use only FORA G71a / TD-4274 test strips and control solutions with the FORA G71a Blood Glucose Monitoring System / TD-4274 Blood Glucose Monitoring System.

5. Substantial Equivalence Information:

Predicate device name: A.

FORA G30/TD-4241 Blood Glucose Monitoring System

B. Predicate K number: K090187
Comparison with predicate: C.

The modified FORA G71a blood glucose monitoring system / TD-4274 Blood Glucose Monitoring Systems have the following similarities to the predicate device:

same operating principle.
same fundamental scientific technology,
incorporate the same basic circuit design.
그 incorporate the same materials.
1 same shelf life
1 packaged using the same materials, and
Manufactured by the same process.

{2}------------------------------------------------

The modifications encompass:

. A modification in the software of the glucose meter
. Modification in the physical appearance
일 Engineering modifications
1 Labeling change due to the software modification
1. Test Principle:

The detection and measurement of glucose in blood is by an electrochemical biosensor technology using glucose oxidase.

1. Performance Characteristics:
  FORA G71a blood glucose monitoring system / TD-4274 Blood Glucose Monitoring System have the same performance characteristics as the predicate device.

A comparison of system accuracy performance demonstrated that the FORA G71a blood glucose monitoring system / TD-4274 Blood Glucose Monitoring System and the currently marketed FORA G30/TD-4241 Blood Glucose Monitoring System are substantially equivalent.

Software verification and validation testing confirmed that the performance, safety and effectiveness of the FORA G71a blood glucose monitoring system / TD-4274 Blood Glucose Monitoring Systems are equivalent to the predicate device.

1. Conclusion:
  Based on the information provided in this submission, the FORA G71a blood glucose monitoring system / TD-4274 Blood Glucose Monitoring System are substantially equivalent to the predicate FORA G30/TD-4241 Blood Glucose Monitoring System.

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features the department's name encircling a stylized symbol. The symbol consists of three abstract human figures. The figures are connected and appear to be in motion.

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002

Taidoc Technology Corporation c/o Ms. Nicky Pan 6f, No. 127, Wugong 2nd Rd, Wugu Township Taipei County, China (Taiwan) 248

FEB 1 9 2010

Re: K093712

Trade/Device Name: Fora G71a Blood Glucose Monitoring System, TD-4274 Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system. Regulatory Class: II Product Code: NBW, CGA Dated: December 3, 2009 Received: January 20, 2010

Dear: Ms. Pan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{4}------------------------------------------------

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely vours.

Cfa

Courtney C. Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Section 8. Indications for Use

Indications for Use

K093712 510(k) Number:

Device Name: FORA G71a Blood Glucose Monitoring System/TD-4274 Blood Glucose Monitoring System

Indications for Use:

The alternative site testing in the FORA G71a Blood Glucose Monitoring System /TD-4274 Blood Glucose Monitoring System can be used only during steady-state blood glucose conditions.

And/Or

Prescription Use (21 CFR Part 801 Subpart D)

Over the Counter Use (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic. Device Evaluation and Safety (OIVD)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k)

Page I of

8-1 of 1

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.